H2 Receptor Antagonists: Clinical Overview
H2 receptor antagonists (H2RAs) are less effective than proton pump inhibitors for treating GERD and healing erosive esophagitis, but remain useful as adjunctive therapy for breakthrough symptoms, step-up approaches in low-risk patients, and NSAID prophylaxis at double doses. 1
Primary H2 Receptor Antagonists and Dosing
Standard Dosing Regimens
For Adults:
- Ranitidine: 150 mg twice daily (standard); 300 mg twice daily (high-dose for NSAID prophylaxis) 2
- Famotidine: 20 mg twice daily (standard); 40 mg twice daily (high-dose)
- Cimetidine: 800 mg at bedtime or 400 mg twice daily 3
- Nizatidine: 150 mg twice daily
For Pediatric Patients 4:
- Cimetidine: 30-40 mg/kg/day divided in 4 doses (FDA approved ≥16 years)
- Ranitidine: 5-10 mg/kg/day divided in 2-3 doses (FDA approved 1 month-16 years)
- Famotidine: 1 mg/kg/day divided in 2 doses (FDA approved 1-16 years)
- Nizatidine: 10 mg/kg/day divided in 2 doses (FDA approved ≥12 years)
Renal Dose Adjustments
For severe renal impairment (CrCl <30-35 mL/min), reduce H2RA doses by approximately 50% without compromising gastrointestinal disease control. 5 A study in frail elderly patients demonstrated that dose reduction based on renal function maintained disease control while potentially improving mortality outcomes (12.1% vs 21.7%, p=0.02).
Clinical Applications by Indication
Gastroesophageal Reflux Disease (GERD)
PPIs are superior to H2RAs for healing esophagitis and symptom relief 1. H2RAs are more effective than placebo but represent second-line therapy. The evidence hierarchy is clear: PPIs > H2RAs > placebo for both healing esophagitis and symptomatic relief (Grade A recommendation).
When to use H2RAs in GERD:
- Breakthrough nocturnal symptoms while on PPI therapy 6
- Step-up approach in patients without erosive esophagitis who fail lifestyle modifications 2
- On-demand therapy for rapid symptom relief due to faster onset of action compared to PPIs 1
- Weaning strategy after PPI therapy in patients without Los Angeles B or greater esophagitis 6
Critical limitation: Tachyphylaxis develops within 6 weeks, limiting long-term efficacy 4. Adding nocturnal H2RA to twice-daily PPI shows no evidence of improved efficacy 1.
Duodenal Ulcer
Single bedtime dosing is highly effective for duodenal ulcer healing. 3 Low bedtime doses (cimetidine 800 mg, ranitidine 150 mg, famotidine 20 mg, nizatidine 150 mg) achieve virtually 100% nocturnal acid inhibition, which correlates with highest ulcer healing rates. This approach exploits physiological meal buffering during daytime while ensuring overnight anacidity.
NSAID-Associated Ulcer Prophylaxis
Standard-dose H2RAs are NOT effective for preventing NSAID-related gastric ulcers 7. However, double-dose H2RAs show effectiveness comparable to standard approaches, though PPIs remain superior 7, 8, 9.
Evidence-based approach:
- High-dose H2RA (e.g., ranitidine 300 mg twice daily) reduces NSAID-associated peptic ulcer risk by 68% compared to low-dose (adjusted RR 0.32,95% CI 0.13-0.79) 8
- PPIs are superior to H2RAs for NSAID ulcer prevention and should be first-line in high-risk patients 7, 10, 9
- H2RAs may be reasonable alternatives in lower-risk patients without history of peptic ulcer 11
High-risk factors requiring PPI over H2RA:
- Prior upper GI bleeding (strongest predictor)
- Advanced age (≥65 years)
- Concomitant antiplatelet agents or anticoagulants
- Helicobacter pylori infection
- High-dose or multiple NSAIDs
- Corticosteroid use
Low-Dose Aspirin
For patients on low-dose aspirin, PPIs are strongly preferred over H2RAs 7, 11. No randomized controlled data support H2RA effectiveness for low-dose aspirin-related injury. The combination of aspirin plus PPI (particularly in patients with prior GI bleeding) provides optimal risk-benefit balance.
Avoid cimetidine with clopidogrel due to competitive CYP2C19 inhibition; other H2RAs are acceptable alternatives if PPI is contraindicated 11.
Pharmacokinetic Considerations
Onset and duration:
- Gastric pH increases within 30 minutes of administration 4
- Peak plasma concentrations at 2.5 hours 4
- Acid-inhibiting effects last approximately 6 hours, necessitating 2-3 times daily dosing 4
Timing strategy: Bedtime dosing exploits circadian acid secretion patterns, providing maximal suppression during peak nocturnal acid production 3.
Adverse Effects and Safety
Common adverse effects are generally mild: headache, diarrhea, constipation, dizziness 4.
Cimetidine-specific concerns:
- Increased risk of liver disease and gynecomastia 4
- Drug interactions via CYP450 inhibition (avoid with clopidogrel, warfarin, phenytoin) 11
- Consider alternative H2RAs (ranitidine, famotidine, nizatidine) to avoid these issues
Aluminum-containing antacids may interfere with H2RA absorption and cause toxicity in renal insufficiency 12.
Clinical Algorithm for H2RA Use
Step 1: Determine indication and risk stratification
- GERD without erosive esophagitis → Consider H2RA as initial therapy or for breakthrough symptoms
- GERD with Los Angeles B or greater esophagitis → Use PPI, not H2RA
- NSAID use with high-risk factors → Use PPI, not H2RA
- NSAID use without high-risk factors → Double-dose H2RA acceptable
- Duodenal ulcer → Single bedtime dose H2RA effective
Step 2: Select agent and dose
- Avoid cimetidine if drug interactions are concern
- Use double-dose for NSAID prophylaxis
- Adjust dose for CrCl <35 mL/min (reduce by 50%)
- Pediatric dosing: weight-based per FDA guidelines
Step 3: Monitor response and adjust
- Assess symptom control at 1-3 months 13
- If inadequate response, escalate to PPI rather than increasing H2RA dose
- Watch for tachyphylaxis after 6 weeks of continuous use
- Consider switching to PPI for long-term maintenance
Step 4: Maintenance strategy
- Use lowest effective dose for symptom control
- Consider on-demand therapy for intermittent symptoms
- Wean to H2RA when stepping down from PPI in appropriate patients (no erosive disease, no Barrett's, no peptic stricture) 6